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Abstract
Background: Healthcare acquired infections (HAI) are an important public health problem in developed countries,
but comprehensive data on trends over time are lacking. Prevalence surveys have been used as a surrogate for
incidence studies and can be readily repeated.
Methods: The Canadian Nosocomial Infection Surveillance Program conducted prevalence surveys in 2002 and
2009 in a large network of major Canadian acute care hospitals. NHSN definitions of HAI were used. Use of isolation
precautions on the survey day was documented.
Results: In 2009, 9,953 acute care inpatients were surveyed; 1,234 infections (124/1000) were found, compared
to 111/1000 in 2002, (p < 0.0001). There was increased prevalence of urinary tract infection (UTI) and Clostridium
difficile, offset by decreases in pneumonia and bloodstream infection. Use of isolation precautions increased from
77 to 148 per 1000 patients (p < 0.0001), attributable to increased use of contact precautions in patients infected
or colonized with antimicrobial resistant organisms.
Conclusion: Between 2002 and 2009 HAI prevalence increased by 11.7 % in a network of major Canadian hospitals
due to increases in Clostridium difficile and urinary tract infection. The use of isolation precautions increased by 92.
2 % attributable to increased contact isolation. National prevalence surveys are useful tools to assess evolving
trends in HAI.
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Background
Hospital acquired infections (HAI) are a common com-
plication of healthcare, but determining their frequency
and assessing trends over time is difficult [1]. For the
most part HAI are not notifiable in Canadian provinces.
Comprehensive continuous surveillance for all HAI
within hospitals is time and labour intensive, consequently
very few hospital Infection Prevention and Control (IPC)
programs conduct this type of surveillance. Nevertheless,
there is a need to determine the extent, subtypes and
trends in HAI over time so that national, provincial
and local practitioners and policy decision makers can
identify priorities for preventive action. Comprehen-
sive, multi-institutional prevalence surveys for the
occurrence of HAI have been adopted as a cost and
time effective alternative to ongoing surveillance for
HAI at national and sub-national levels [2–6]. By
repeating such surveys trends can be accurately
assessed [7].
The Canadian Nosocomial Infection Surveillance
Program (CNISP) has conducted HAI surveillance in a
network of Canadian hospitals since 1993. CNISP
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conducted surveys for the prevalence of HAI within net-
work hospitals in 2002 and again in 2009, and has previ-
ously reported partial results [8–10]. In preparation for a
possible repeat national survey, we wished fully compare
the results of the two previous surveys to determine
which developing areas may require further in-depth
future review. In this report we fully describe the assess-
ment of HAI prevalence and use of isolation precautions
in patients in CNISP hospitals in 2009, compare the
results to our 2002 survey, and discuss the ongoing value
of HAI prevalence surveys based on these comparisons.
Methods
CNISP, a network of acute care hospitals from 10
Canadian provinces, is a partnership between the Public
Health Agency of Canada (Agency) and the Canadian
Hospital Epidemiology Committee, a group of hospital-
based physician infection prevention specialists. The
number of hospitals participating in CNISP increased
from 32 in 2002 to 50 hospitals in 2009; 7(14 %) are
standalone pediatric centres. Surveillance for HAI in
participating hospitals is considered to be a quality
assurance activity within the mandate of hospital infec-
tion prevention and control programs and, therefore,
does not constitute human research, therefore research
ethics committee approval was not needed for this
study.
Twenty-five (25) acute-care CNISP member hospitals
with 6 pediatric hospitals and 19 combined pediatric and
adult hospitals in eight provinces participated in a one-
day HAI point-prevalence survey in February 2002. In
February 2009, 49 hospitals including 7 pediatric and 42
combined pediatric and adult hospitals carried out a
point-prevalence study. To ensure comparability of
results, definitions of HAI, and case finding by chart
review were identical in the 2002 and 2009 surveys. In
both surveys, chart reviewers underwent pre-study train-
ing regarding HAI definitions and chart review methods.
Information on HAI, utilization of antimicrobial agents
and use of isolation precautions was collected. Patients
were identified by a ward census list obtained at a pre-
specified time on the day the survey was conducted.
Patients on long term care units, psychiatric units, re-
habilitation units, maternity wards, well baby units and




N = 8565 (86.1 %)
Children
N = 622 (6.2 %)
Infants
N = 729 (7.3 %)
N % N % N % N %
Male Genderb 5101 51.3 4367 51.3 324 52.1 394 54.0
Unit Type
Medicine/Pediatric 3840 38.6 3501 40.9 226 36.3 101 13.9
Surgery 2959 29.7 2802 32.7 123 19.8 25 3.4
Intensive Care 1141 11.5 532 6.2 53 8.5 551 75.6
Oncology/Hematology 350 3.5 244 2.8 98 15.8 6 0.8
Critical Cared 233 2.3 233 2.7 0 0 0 0
Transplant 177 1.8 139 1.6 33 5.3 4 0.5
Trauma 76 0.8 71 0.8 2 0.3 3 0.4
Gynecology/Obstetrics 157 1.6 146 1.7 0 0 7 1.0
Others 1020 10.2 897 10.5 87 14.0 32 4.4
Total 9953 100 8565 100 622 100 729 100
Receiving antimicrobial agent(s) 3998 40.2 3442 40.2 329 52.9 214 29.4
Isolation Precautionsc
None 8483 85.2 7322 85.5 483 77.7 648 88.9
Droplet 258 2.6 114 1.3 87 14.0 55 7.5
Air 75 0.8 53 0.6 15 2.4 6 0.8
Contact 1316 13.2 1136 13.3 110 17.7 64 8.8
Other 7 0.07 4 0.05 2 0.32 1 0.14
HAI Presente 1173 11.8 1053 12.3 66 10.6 52 7.1
aAdults are defined as 18 years of age and older, children age 1–17 years of age, and infants as under 1 year of age
bDoes not add to 9953 due to missing data
cColumns add up to a number greater than sample size due to patients being in multiple types of isolation
d Critical care refers to those patients in critical and coronary units with or without mechanical ventilation
eHAI Health care associated infections
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day surgery units were excluded. No patient was en-
rolled more than once during the surveillance period.
The primary outcome was the presence of an HAI,
which was defined as an infection not present on admis-
sion and with onset at least 72 h after admission. The
study was limited to the following infections: hospital
acquired pneumonia (HAP), urinary tract infection
(UTI), bloodstream infection (BSI), surgical site infection
(SSI) and Clostridium difficile infection (CDI). CDC/
NHSN definitions for nosocomial infection were used
for all HAI [11]. Isolation precautions beyond routine
practices (Additional Precautions) were categorized as
defined by the Public Health Agency of Canada [12].
Patient information was collected on manually com-
pleted data forms and included: date of admission,
the admitting medical or surgical service, antimicro-
bial agents received on the day of the survey, and
isolation precautions in place on the survey day. After
testing for normality, prevalence ratios were calculated
and differences between infected and non-infected pa-
tients were assessed using a Wald test for categorical vari-
ables and a Student’s t-test for continuous variables. All
tests were two-tailed, and P < 0.05 was considered
statistically significant. Data analysis was performed using
SAS version 8.1 (SAS Institute, Cary, NC,USA).
Results
In the 2009 survey 9,953 patients were evaluated; 8,565
(86.1) were adults (>18 years of age). 622 (6.4) were 1 to
17 years of age, and 729 (7.3 %) were infants under the
age of 1 years. Table 1 describes characteristics of sur-
veyed patients. There were 1,231 HAI identified in 1,173
patients (11.8); 1,470 patients (16.7) were on isolation
precautions and 3,998 (40.2 %) were receiving antimicro-
bial agents. Table 2 compares characteristics of HAI and
non – HAI patients in 2009. HAI were more common
in Surgery and Critical Care patients, and less frequent
in Medicine and Obstetrics-gynecology patients. Patients
with HAI were somewhat older and more likely to be on
surgical or Intensive Care units than non-HAI patients,
and more likely to be on isolation precautions and re-
ceiving antimicrobial therapy. Table 3 subdivides HAI
types into Adult, Children and Infant categories,
highlighting the major variation in HAI prevalence by
age category. Table 4 compares the frequency and distri-
bution of HAI in 2002 and 2009. In 2009 the prevalence






N % N %
Age in years ± SD 57.9 ± 27.7 62 ± 25
Median (min-max) 65 (0–108) 68 (0–99)
Male Gendera 4492 51.2 609 51.9 0.6409
Unit Type
Medicine/Pediatric 3455 39.4 385 32.8 <0.0001
Surgery 2577 29.4 382 32.6 0.0248
Intensive Care 934 10.6 207 17.6 <0.0001
Oncology/Hematology 313 3.6 37 3.2 0.5543
Critical Carec 221 2.5 12 1.0 0.0007
Transplant 153 1.7 24 2.0 0.4794
Trauma 70 0.8 6 0.5 0.3720
Gynecology/Obstetrics 149 1.7 8 0.7 0.0058
Others 908 10.3 112 9.5 0.4419
Receiving antimicrobial agent(s) 2925 33.3 1073 91.5 0.0001
Isolation Precautionsb
None 7649 87.1 83.4 71.1 0.0001
Droplet 209 2.3 49 4.2 0.0001
Air 72 0.8 3 0.3 0.0305
Contact 1000 11.4 316 26.9 0.0001
Other 5 0.06 2 0.2 0.1955
aDoes not add to 8780 due to missing data
bColumn adds up to a number greater than sample size due to patients being in multiple types of isolation
cCritical care refers to those patients in critical and coronary units with mechanical ventilation
dHAI is the abbreviation for Health care associated infections
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of HAI was 124 per 1000 patients surveyed, compared
with 111 per 1000 in surveyed in 2002 (p < 0.0001).
Between the two surveys there was a significant increase
in the prevalence of UTI (from 3.0 to 4.3) and CDI
(from 0.8 to 1.2 %). HAP and BSI both slightly, but
significantly, decreased in prevalence. Surgical site infec-
tions were unchanged.
Figure 1 illustrates changes in prevalence of use of iso-
lation precautions (beyond routine practices) on the
survey day. There was a near doubling of use of Add-
itional Precautions, from 77/1000 survey patients in
2002 to 148/1000 in 2009 (p < 0.0001), almost entirely
driven by increased Contact Precautions (from 63 to
132/1000 patients). Figure 2 illustrates conditions re-
sponsible for precautions in the two surveys. As
indications for precautions, MRSA, CDI and VRE were
all significantly increased in 2009 compared to 2002.
Discussion
CNISP has carried out two national surveys to estimate
the prevalence of HAI in Canadian hospitals. The num-
ber of hospitals participating increased between the two
surveys (from 25 in 2002 to 49 in 2009), however, the
nature of the CNISP, hospitals network did not signifi-
cantly change. Most are large urban teaching hospitals
[13]. By using an identical survey tool, and standard
HAI definitions for the two surveys we hoped to then
evaluate changes in frequency of HAI (and related con-
cepts, such as isolation precautions, and use of anti-
microbial agents) in hospitalized patients. Based on
these surveys, there was an 11.7 % increase in prevalence
of HAI between 2002 and 2009, largely driven by in-
creases in UTI and CDI, partially offset by reductions in
HAP and BSI. Explanations for these changes are specu-
lative. In Canada, as elsewhere, as less acutely ill patients
are increasingly managed in ambulatory settings the
residual core of hospitalized patients may have higher
acuity, and so may be more prone to HAI. The change
in distribution of HAI is of interest. As central venous
catheter and ventilator associated pneumonia (VAP)
prevention bundles are implemented, reduced preva-
lence of BSI and HAP may occur [14,15]. We have
previously documented increased incidence of CDI in
CNISP hospitals [16]. An explanation for increased
Table 3 Prevalence of healthcare-associated infections identified during the 2009 point prevalence survey (N = 1173)
Type of HAI All HAI Patients
n = 1173
HAI Adults
n = 1053 (90 %)
HAI Children
n = 66 (6 %)
HAI Infants
n = 52 (4 %)
No. % No. % No. % No. %
Urinary Tract 428 34.8 414 39.0 5 0.4 8 0.7
Pneumonia Total 268 21.8 248 20.2 16 1.3 4 0.3
VAP 82 6.7 71 5.8 8 0.7 3 0.2
Non VAP 175 14.2 167 13.6 7 0.6 1 0.1
Surgical Site Total 214 17.4 200 16.3 10 0.8 4 0.3
PI related 63 5.1 58 4.7 5 0.4 0 0
Non PI related 133 11 124 10.1 5 0.4 4 0.3
Blood Stream Total 169 13.8 131 10.6 15 1.2 23 1.9
Primary, non CVC-BSI 73 5.9 48 3.9 11 0.9 14 1.1
Primary, CVC-BSI 29 2.4 19 1.5 2 0.2 8 0.7
Secondary 63 5.1 60 4.9 2 0.2 1 0.1
CDI 115 9.3 110 8.9 4 0.3 0 0
Viral Respiratory Illness 17 1.4 5 0.4 9 0.7 3 0.2
Viral Gastroenterocolitis 17 1.4 0 0 10 0.8 7 0.6
NEC 3 0.2 0 0 0 0 3 0.2
Total + 1231 100 1108 90.0 69 5.6 52 4.2
Abbreviations: VAP ventilator-associated pneumonia, PI prosthetic implant, CVC-BSI central venous catheter associated blood stream infection, CDI Clostridium
difficile infection, NEC Necrotizing enterocolitis
Table 4 Comparison of Prevalence of Healthcare Associated
Infections in CNISP Hospitals in 2002 and 2009
2002 2009 P value
Participating Hospitals 25 49
Surveyed patients 6747 9953
Prevalencea 111 124 p <0.0001
Urinary tract 3.0 % 4.3 % p <0.0001
Surgical site 2.3 % 2.3 % p > 0.05
Pneumonia 2.9 % 2.7 % p <0.0001
Blood stream 1.8 % 1.7 % p <0.0001
Clostridium difficile 0.8 % 1.2 % p <0.0001
aper 1000 survey patients
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prevalence of UTI is not apparent. The factors
responsible for changing HAI distribution in Canada
require further research.
Our data indicates that there was a substantial in-
crease in use of isolation precautions in CNISP hospitals
between 2002 and 2009, primarily as a result of in-
creased use of Contact Precautions (CP). This increase
in CP was associated with increased need for isolation of
patients due to CDI, methicillin resistant Staphylococcus
aureus (MRSA) and vancomycin resistant enterococci
(VRE). CNISP has documented increased incidence of
all of these microorganisms over the last decade [16–18].
Our prevalence surveys are observational and cannot
readily assess the effectiveness of CP in limiting increase
in CDI, MRSA or VRE frequency. Isolation precautions
are used in hospitalized patients to interrupt transmission
of organisms [19]. While there has been concern that
transmission precautions may have adverse patient effects
[20], a study of routine CP in ICU patients found no in-
crease in adverse patient events [21] and a cohort study of
non ICU patients found that patients on CP had a reduced
frequency of non-infectious adverse events [22]. However
Dhar et al. found that as the proportion of patients in CP
increased, compliance with precautions decreased [23].
There is an emerging trend to reduce use of CP for some
conditions, particularly for patients with VRE [24–27] but
more research is needed to determine the most effective
approach to isolation precautions in acute care settings.
Despite the relatively short interval between our two
surveys, we have documented substantial changes in
HAI prevalence and distribution, use of antimicrobial
therapy [10] and use of isolation practices in Canadian
acute care hospitals. The CNISP hospital network ex-
panded in the years between the two surveys. While the
nature of the hospitals did not systemically change, this
represents a limitation in comparing results of the two
surveys. CNISP hospitals are primarily tertiary care
teaching and/or large urban referral hospitals [13]. This
represents a limitation in the representativeness of
CNISP amongst Canadian hospitals. In addition studies
evaluating results of incidence and prevalence studies in-
dicate that there is not a direct correlation between
prevalence and incidence [28].
The information we report are now seven years old
which is a major limitation in the data presented. It
seems likely that the developing trends we have docu-
mented between 2002 and 2009 may have continued
since then. Front line practitioners and healthcare ad-
ministrators have an urgent need for more up to date
data to permit IPC programs to be developed and
Fig. 1 Patients on additional precautions
Fig. 2 Reasons for additional precautions in surveyed patients
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modified in response to the changing pattern of HAI in
Canada. Consequently a repeat survey is a high priority
for our network. Neverthless these data currently repre-
sents the only comprehensive estimates of the occurance
of HAI in Canadian hospitals.
Conclusion
Between 2002 and 2009 in a network of acute care hos-
pitals in Canada HAI prevalence increased from 111 to
124 per 1000 patients. The use of isolation precautions
increased from 77 to 148 per 1000 patients.
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